Morphea often follows relapsing-remitting course

And MRI can be useful to track deep disease, researchers say

Morphea, or localised scleroderma, often follows a relapsing-remitting course over several years, but existing therapies appear to improve disease activity and stabilise damage, researchers report.

Balck and white image of MRI scanner

In two reports in JAMA Dermatology, US researchers investigated the disease course in patients with morphea treated with standard-of-care therapy and compared clinical assessment of deep morphea with MRI findings.

The first study included 130 adults and children (mean age 34 years, 78%